ArticleInternational surgery
Low serum interleukin-13 levels correlate with poorer prognoses for colorectal cancer patients.
Article in International surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Prognostic significance of pre-intervention circulating cytokines in digestive system cancers: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Context-Dependent Survival Associations Between Interleukin-13 Expression and Immunotherapy in Advanced Solid Tumors.ImmunoTargets and therapy · 2026Article
- Multi-Omics-Based Analysis of the Effect of Longevity Genes on the Immune Relevance of Colorectal Cancer.Biomedicines · 2025Article
- Article
- Article
- Possible Roles of Interleukin-4 and -13 and Their Receptors in Gastric and Colon Cancer.International journal of molecular sciences · 2021Review
- Identification of Molecular Subtypes and a Prognostic Signature Based on Inflammation-Related Genes in Colon Adenocarcinoma.Frontiers in immunology · 2021Article
- Article
- Innate Lymphoid Cells in Colorectal Cancers: A Double-Edged Sword.Frontiers in immunology · 2019Review
- Receptor-Targeted Glial Brain Tumor Therapies.International journal of molecular sciences · 2018Review
- CD68 and interleukin 13, prospective immune markers for esophageal squamous cell carcinoma prognosis prediction.Oncotarget · 2016Article
- Serum cytokine profile as a potential prognostic tool in colorectal cancer patients - one center study.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation OncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-13 (IL-13) is an immunosuppressive cytokine produced by several immune cells and cancer cells. The aim of this retrospective study was to determine if serum IL-13 levels have an association with clinical outcome in patients with colorectal cancer. A total of 241 patients with colorectal cancer were enrolled in the present study. Preoperative serum IL-13 concentrations were measured by enzyme-linked immunosorbent assay. We analyzed the association of serum IL-13 levels with clinicopathological variables. Patients with lymph node metastasis, lymphatic invasion, vascular invasion, distant metastases or advanced stage of disease had significantly lower serum IL-13 levels. Low serum IL-13 was significantly associated with both poor recurrence-free and overall survival. Multivariate analysis showed that low IL-13 levels were an independent predictive marker for poor prognosis. In conclusion, our data suggest that low serum IL-13 levels may be a useful predictive marker for poor prognosis in colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.